English
This article is from Indian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India , volume 27 . Abstract Introduction:: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. Materials and Methods:: Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. Results:: BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the
Sign in with your free account to read, download EPUBs or listen.
Ebook · Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. · Kamaleshwaran, Koramadai Karuppusamy, Mittal, Bhagwant Rai, Harisankar, Chidambaram Natrajan Balasubramanian, Bhattacharya, Anish, Singh, Shrawan Kumar, Mandal, Arup K · Internet Archive